Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.
Patients suffering from rheumatoid arthritis are treated for around six months with the standard anti-rheumatic agent methotrexate, to which many patients respond very well.
The results of a study presented today at the Annual European Congress of Rheumatology 2017 have confirmed that Fluorescence Optical Imaging, a technique used to visualize inflammation in arthritic joints, is as effective as ultrasound with Power Doppler (US / PD) at monitoring response to treatment in juvenile idiopathic arthritis.
A clinical trial funded by Arthritis Research UK and the National Institute for Health Research led by professors from the Universities of Liverpool and Bristol has discovered a drug combination that could help thousands of children with arthritis.
Although anti-inflammatory treatments are quite effective at reducing symptoms in patients with Crohn's disease and ulcerative colitis, the mucosal lining of the intestine often remains ulcerated, and many patients still ultimately require surgery.
Amgen and Allergan plc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin (bevacizumab).
The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases.
Patients suffering from noninfectious uveitis, a group of diseases that causes eye inflammation, can get effective treatment from a corticosteroid alternative that has previously been approved for treatment of arthritis and Crohn's disease, according to a study led by a Duke Health researcher.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies for rare and serious diseases, announced today that Nature Nanotechnology has published an article that presents preclinical results from Selecta’s research which demonstrate the broad potential applicability of Selecta’s novel immune tolerance platform.
Prescription medication costs are expected to rise at least 11 percent, and possibly up to 13 percent, in 2016, according to a new report on national trends and projections in prescription drug expenditures.
The results of a study presented today at the European League Against Rheumatism Annual Congress showed that a range of factors other than just cost may influence the prescribing of TNF inhibitors for patients with rheumatoid arthritis (RA).
Researchers from University College London have discovered that the widely used antiinflammatory drug HUMIRA doesn't just work by inhibiting its target protein, TNF, but by enhancing a particular function of TNF in rheumatoid arthritis patients.
About half of Medicare patients who start taking biologic therapies for moderate to severe plaque psoriasis stop within a year, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA) in improving signs and symptoms in patients with active rheumatoid arthritis (RA) at Week 24.
Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology.
The new BSR guidelines make a number of specific recommendations for the use of standard and/or biologic disease modifying anti-rheumatic drugs (DMARDs), providing crucial advice for clinicians, obstetricians and midwives.
Results published today in The New England Journal of Medicine from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 2b trial showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared psoriasis or minimal psoriasis at week 16, the study's primary endpoint.
A phase II clinical trial led by Northwestern Medicine investigators shows that a new psoriasis drug called guselkumab has greater efficacy than the current standard of care for the chronic skin condition.
A study of 311 patients by The University of Manchester has found that it may be possible to predict early which rheumatoid arthritis (RA) patients will fail to respond to the biologic drugs given to treat them.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody ("mAb") technology. 3SBio previously acquired the China rights from Apexigen in 2006.
The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that, in rheumatoid arthritis (RA) patients, a good clinical response to maintenance treatment with a tumour necrosis factor inhibitor (TNFi) was maintained even when the dose was reduced by one-third.